# A Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination With Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer

> **NCT01311050** · — · UNKNOWN · sponsor: **King Faisal Specialist Hospital & Research Center** · enrollment: 46 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Capecitabine (Xeloda), Oxaliplatin, Irinotecan, Bevacizumab

## Key facts

- **NCT ID:** NCT01311050
- **Lead sponsor:** King Faisal Specialist Hospital & Research Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-01
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2011-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01311050

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01311050, "A Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination With Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01311050. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*